Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,035 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,952 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00354120 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant(GLOBAL) | completed | Phase 2 / Phase 3 | 121 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT02419287 | Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas | completed | Phase 2 | 12 | University of Milano BicoccaOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT05338047 | Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant | completed | Phase 2 | 30 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 50 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT01066663 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT00796068 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | completed | Phase 2 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03019640 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02853370 | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma | completed | Phase 2 | 78 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 2 | Feb 1, 2023 | clinicaltrials |
| NCT00005780 | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma(STORM) | completed | Phase 2 | 202 | Karyopharm Therapeutics IncINDUSTRY | 6 | Jan 26, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02342665 | Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL | completed | Phase 1 / Phase 2 | 25 | BayerINDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02807883 | Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03109353 | Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | completed | Phase 1 / Phase 2 | 7 | St. Olavs HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | completed | Phase 2 | 136 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | completed | Phase 2 | 55 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT01141712 | Autologous Transplant in HIV Patients (BMT CTN 0803) | completed | Phase 2 | 43 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02440464 | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | completed | Phase 2 | 57 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | completed | Phase 2 | 14 | AbbVieINDUSTRY | 9 | Dec 19, 2022 | clinicaltrials |
| NCT00864227 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | completed | Phase 2 | 54 | Medical College of WisconsinOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT03877055 | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT00912223 | Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) | completed | Phase 2 | 65 | Medical College of WisconsinOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT01410344 | Allogeneic Transplant in HIV Patients (BMT CTN 0903) | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02604511 | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02802943 | iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL | completed | Phase 2 | 56 | University Hospital TuebingenOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03187262 | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 2 | 17 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT02963493 | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(HORIZON) | completed | Phase 2 | 157 | Oncopeptides ABINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 331 | Hoffmann-La RocheINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT02572167 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 93 | Seagen Inc.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03200015 | Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02654132 | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | completed | Phase 2 | 117 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 1, 2022 | clinicaltrials |
| NCT02722941 | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01807611 | Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | completed | Phase 2 | 82 | St. Jude Children's Research HospitalOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT03505996 | A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 82 | CStone PharmaceuticalsINDUSTRY | 1 | Oct 31, 2022 | clinicaltrials |
| NCT02660710 | Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma | completed | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03770000 | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | completed | Phase 1 / Phase 2 | 33 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01859819 | Treatment for Advanced B-Cell Lymphoma(REBOOT) | completed | Phase 2 | 45 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Mar 10, 2023source: clinicaltrials